Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7QL8

SARS-COV2 Main Protease in complex with inhibitor MG78

これはPDB形式変換不可エントリーです。
7QL8 の概要
エントリーDOI10.2210/pdb7ql8/pdb
分子名称3C-like proteinase nsp5, (1R,2S,5S)-N-{(2S,3R)-4-amino-3-hydroxy-4-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl}-3-[N-(tert-butylcarbamoyl)-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, CHLORIDE ION, ... (5 entities in total)
機能のキーワードinhibitor complex, sars-cov2, viral protein
由来する生物種Severe acute respiratory syndrome coronavirus 2
タンパク質・核酸の鎖数1
化学式量合計33925.09
構造登録者
El Kilani, H.,Hilgenfeld, R. (登録日: 2021-12-19, 公開日: 2022-04-27, 最終更新日: 2024-11-20)
主引用文献Gohl, M.,Zhang, L.,El Kilani, H.,Sun, X.,Zhang, K.,Bronstrup, M.,Hilgenfeld, R.
From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease.
Molecules, 27:-, 2022
Cited by
PubMed Abstract: The main protease (M) of the betacoronavirus SARS-CoV-2 is an attractive target for the development of treatments for COVID-19. Structure-based design is a successful approach to discovering new inhibitors of the M. Starting from crystal structures of the M in complexes with the Hepatitis C virus NS3/4A protease inhibitors boceprevir and telaprevir, we optimized the potency of the alpha-ketoamide boceprevir against the M by replacing its P1 cyclobutyl moiety by a γ-lactam as a glutamine surrogate. The resulting compound, , exhibited an IC of 13 nM versus the recombinant M, and similar potency was observed for its P1' -methyl derivative . Crystal structures confirmed the validity of our design concept. In addition to SARS-CoV-2 M inhibition, we also explored the activity of against the M of the alphacoronavirus HCoV NL63 and against enterovirus 3C proteases. The activities were good (0.33 µM, HCoV-NL63 M), moderate (1.45 µM, Coxsackievirus 3C), and relatively poor (6.7 µM, enterovirus A71 3C), respectively. The structural basis for the differences in activities was revealed by X-ray crystallo-graphy. We conclude that the modified boceprevir scaffold is suitable for obtaining high-potency inhibitors of the coronavirus Ms but further optimization would be needed to target enterovirus 3Cs efficiently.
PubMed: 35807537
DOI: 10.3390/molecules27134292
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.807 Å)
構造検証レポート
Validation report summary of 7ql8
検証レポート(詳細版)ダウンロードをダウンロード

246905

件を2025-12-31に公開中

PDB statisticsPDBj update infoContact PDBjnumon